Emerging evidence has indicated that the expression of SPOCD1 is a prognostic factor in several tumors, including gastric cancer, clear cell renal cell carcinoma, ovarian cancer, osteosarcoma, and glioma (Zhu et al., 2017; Liang et al., 2018; Liu et al., 2018; Sakaguchi et al., 2018; Liu et al., 2020). This evidence concerns the gene SPOCD1 and central nervous system cancer.